A phase II study of
CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
Initially, the collaboration will concentrate on the development of next-generation product candidate to TheraBiologics' TBX02, which uses an established NSC line engineered to express a modified carboxylesterase enzyme that converts the prodrug,
CPT-11 (Irinotecan), to the potent chemotherapy agent, SN-38, which is 1000x more toxic to cancer cells than
CPT-11.
Including acetaminophen and the chemotherapy medication
CPT-11.
Activity of
CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
A retrospective study of bifractionated
CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and
CPT-11 containing chemotherapies
Colorectal cancer patients were treated with oxaliplatin plus 5-fluorouracil (5-FU), or weekly
CPT-11 or 5-FU and folates (FA).
CPT-11 has shown anticancer activity against a variety of solid tumors in clinical trials, including colorectal cancer, gynecologic cancers, non-small cell and small cell lung cancers, and refractory cervical cancer (5-11).
In 1994 AIDS Treatment News reported on a class of drugs being developed for cancer, but not for HIV, though some experts believed they should be tested as antiretrovirals (see Topotecan,
CPT-11 (Irinotecan), Camptothecin, and Other Topoisomerase I Inhibitors, AIDS Treatment News #197, April 15, 1994).
The roles of Taxol-like drugs,
CPT-11, gemcitabine, and vinorelbine are still being sorted out in clinical trials, Dr.
One example is the use of an enzyme attached to the fusion protein to activate the cancer drug, camptothecin, or
CPT-11 (Camptosar), which is being sold by Pharmacia & Upjohn (Branchburg, NJ) as a therapeutic for colorectal cancers, at the tumor sites.
6 October 2010 - US-based biopharmaceutical company Enzon Pharmaceuticals Inc (NASDAQ: ENZN) announced yesterday the publication of preclinical data demonstrating that PEG-SN38 (EZN-2208), the company's novel PEGylated DNA topoisomerase I inhibitor, led to significantly greater tumor regression as compared to
CPT-11 (irinotecan) in both in vitro and in vivo models of pediatric neuroblastoma.
Such a study has been performed by the UK Fluorouracil, Oxaliplatin and
CPT-11 (irinotecan), Use and Sequencing (FOCUS) II investigators for a fluoropyrimidine [+ or -] oxaliplatin and demonstrated a limited advantage of oxaliplatin-based combination therapy in elderly patients [19].
